Nature of Business (Details) - USD ($)		1 Months Ended	12 Months Ended
	Mar. 17, 2020	Mar. 23, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Nature of Business (Textual)
Cash and cash equivalents			$ 5,420,708	$ 8,983,717	$ 7,809,487
Net change in cash and cash equivalent			$ (3,563,009)	1,174,230
Percentage change in cash and cash equivalent			40.00%
Cash in operations			$ (7,509,567)	(7,244,631)
Working capital			1,181,249	6,131,178
Accumulated deficit			(175,525,612)	(166,170,020)
Decrease in cash and cash equivalents			4,949,929
Net loss			$ (9,355,592)	$ (8,899,975)
Remaining from FBR sales agreement, description			The Company has up to $x.x million remaining from the FBR Sales Agreement as of March 23, 2020 under the prospectus supplement updated October 3, 2018.
Contracts from NIH and NIAID, description			The Company is currently developing RiVax® under a NIAID contract of up to $24.7 million over six years, and SGX301 and SGX942 under two separate NIH grants of approximately $1.5 million each over two years, and a one-year NIH grant of $150,000 in support of its SGX942 pediatric program. In addition, the Company has a subcontract of approximately $700,000 from a NIAID grant over five years for its thermostabilization technology, and a Defense Threat Reduction Agency subcontract of approximately $600,000 over three years for SGX943.
Subsequent Event [Member]
Nature of Business (Textual)
Common stock issued	1,956,182	1,732,115
Weighted average price per share		$ 2.30